- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
SZC Shows Superior Efficacy and Safety Over SPS in Treating Hyperkalemia in hemodialysis patients: Study

Data from a new clinical trial revealed that compared to sodium polystyrene sulfonate (SPS) treatment, Sodium zirconium cyclosilicate (SZC) provided faster and more effective resolution of hyperkalemia, with a potentially improved safety profile and better palatability in hemodialysis patients. The findings were published in the BMC Nephrology journal.
Hyperkalemia is a frequent and potentially fatal complication in patients receiving maintenance dialysis. Despite the widespread use of potassium binders like SPS, comparative data on newer therapies has remained limited, until now.
This multicenter, double-blinded, randomized clinical trial enrolled 120 HD patients with predialysis serum potassium levels exceeding 5 mmol/L. Participants were assigned to receive either SZC (5 grams, thrice weekly on non-dialysis days, totaling 15 grams per week) or SPS (15 grams, thrice weekly, 45 grams per week) over an 8-week period. The primary outcome was the change in serum potassium levels during the treatment phase.
The results found both groups to experience a statistically significant reduction in serum potassium levels beginning in the first week and continuing throughout the study period (p < 0.001 for both groups). However, SZC outpaced SPS in bringing patients into the normal potassium range (normokalemia), achieving this milestone by the second week, whereas SPS-treated patients did not reach normokalemia until the sixth week (p < 0.001).
The rescue therapy for hyperkalemia was used when potassium levels pose an acute risk, was required less often in the SZC group (3.3%) when compared to the SPS group (6.6%), although this difference was not statistically significant (p = 0.678).
Gastrointestinal side effects, a known concern with potassium binders, were reported by 5% of patients in the SZC group and 11.6% in the SPS group, a non-significant difference. However, palatability emerged as a clear differentiator. SZC was rated as significantly more palatable than SPS (p < 0.001), an advantage that could enhance patient compliance.
While both agents demonstrated safety and effectiveness in lowering potassium levels, the study's data suggest SZC may offer a faster, better-tolerated, and more patient-friendly alternative to the traditional SPS approach.
The study data compared weekly average serum potassium levels between the two groups over the 8-week trial. SZC-treated patients saw a sharper and earlier decline in potassium, with normalization occurring by week 2. In contrast, SPS showed a more gradual decrease, achieving normokalemia only by week 6.
Additionally, gastrointestinal side effects and the need for rescue therapy were numerically lower in the SZC group. Patient-reported palatability scores strongly favored SZC, reinforcing its potential advantages in clinical practice.
Source:
Elsayed, M. M., Abdelrahman, M. A., Sorour, A. M., Rizk, I. G., & Hassab, M. A. A. (2025). Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial. BMC Nephrology, 26(1). https://doi.org/10.1186/s12882-025-04129-9
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751